Figure 3From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer Kaplan-Meier curves are shown comparing the overall survival of patients with different epigenotypes of SFRP5 (A), WIF1 (B), or different genotype of EGFR (C). Back to article page